Reports Q4 revenue $45.7M, consensus $45.74M. “Fourth quarter procedure revenue increased approximately 6.6%, reflecting stability for our hormone optimization therapies,” said Terry Weber, Biote Chief Executive Officer. “Over the year, we also continued to expand our nationwide network, growing the net number of Biote-certified practitioners to more than 7,100.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BTMD:
- 3 Best Stocks to Buy Now, 2/22/2024, According to Top Analysts
- Biote Corp. Settles Litigation and Repurchases Founder’s Shares
- B. Riley starts Biote with Buy on horome replacement therapy potential
- Biote initiated with a Buy at B. Riley
- Biote initiated with a Buy at Jefferies with ‘platform revving up’
